Hui Zhang, PhD
Neurocrine Biosciences, Inc., San Diego, California
Narrative Review
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
April 29, 2026
The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
